No Data
No Data
Outlook Therapeutics(R) (NASDAQ: OTLK) to Participate Virtual Investor Closing Bell Series
Outlook Therapeutics to Present at the Virtual Investor Pitch Conference
Outlook Therapeutics(R) (NASDAQ:OTLK) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
Watch the "What This Means" video hereOutlook CEO, Russ Trenary underscores that LYTENAVA (bevacizumab gamma) has become the first ophthalmic formulation of bevacizumab to receive European Commission
Buy Rating Justified by Outlook Therapeutics' Advancements and Market Prospects
Express News | Outlook Therapeutics Gains Marketing Authorization From European Commission For LYTENAVA To Treat Retina Diseases
Express News | Outlook Therapeutics Inc - Strategic Partnership With Cencora (Formerly Amerisourcebergen) to Support Planned Commercial Launches of Lytenava in EU
No Data